Identification of Novel Drug Targets and Lead Compounds for Advanced Prostate Cancer through Genomic and Cheminformatic Analyses
Annual rept. 1 Aug 2014-31 Jul 2015
BRITISH COLUMBIA UNIV VANCOUVER
Pagination or Media Count:
Prostate cancer PCa is one of the mo st common cancers for males in the United States and Canada. When PCa is diagnosed early, it can be treated by surgery or radiation. However, in about 30 of cases when PCa recurs or metastasizes, the disease is managed primarily by hormone therapy. Unfortunately, the effectiveness of this therapy is temporary due to emerging resistance mechanisms. Thus, the limited effectiveness and side effects of current PCa treatments demand for new therapeutics to treat advanced PCa. With the accumulated publicly available genomic data and recent advancements in bioinformatic and cheminformatic algorithms, this research project aims to apply comprehensive analyses of cancer genomes and transcriptomes to identify new drug targets, followed by the discovery of lead compounds through virtual screening techniques and biological assays. The outcome of this project can lead to new generations of anti-PCa drugs to treat cases where the cancer cells have developed resistance to existing drugs, by targeting other alternative pathways.
- Genetic Engineering and Molecular Biology
- Anatomy and Physiology
- Medicine and Medical Research